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The interaction between hosts and the viruses that infect them is a dynamic one, and a growing literature documents the
fact that many viruses have developed mechanisms designed to avoid elimination by the host immune system. One of the
immune strategies used by the host and targeted by virus proteins is apoptosis triggered by the cytokine tumor necrosis
factor (TNF). Mouse fibroblast LM cells are spontaneously sensitive to TNF. When the wild-type E6 protein from the human
papillomavirus type 16 (HPV 16) was expressed in LM cells, the cells became resistant to TNF. This resistance was examined
by several means, including cell morphology, the dose- and time-independent response to TNF in a cell death ELISA, trypan
blue exclusion, and cell proliferation. The level of p53 did not rise in TNF-treated cells prior to apoptosis, suggesting a
p53-independent mechanism. Significant, though not complete, resistance to TNF was also observed following transfection
of a plasmid expressing a mutant E6 protein, which is unable to mediate rapid degradation of the p53 tumor suppressor.
These results indicate that the HPV 16 E6 protein can protect LM cells from TNF-triggered apoptosis and likely does so by
a mechanism other than mediation of p53 degradation. © 1999 Academic Press
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pINTRODUCTION
High-risk strains of the human papillomavirus (HPV),
uch as 16 and 18, code for two oncoproteins, E6 and E7
see Howley et al., 1992; Munger et al., 1992; Vousden,
993, for reviews). The best-characterized function of the
6 protein is the binding of wild-type p53; this action
ediates its rapid ubiquitination and degradation. E6
oes this in conjunction with the cellular E6-associated
rotein (E6-AP) (Huibregtse et al., 1991; Scheffner et al.,
990, 1993). This loss of p53 has significant biological
ffects, because p53 serves as an anti-oncoprotein by
ediating growth arrest and/or apoptosis in cells with
amaged DNA. For example, the ability of E6 proteins to
ediate this rapid p53 degradation correlates with their
bility to block G1 growth arrest caused by DNA damage
Foster et al., 1994; Kessis et al., 1993). E6 inhibits the
ranscriptional activity of p53 (Meitz et al., 1992), and the
resence of E6 from “high-risk” strains of HPV is perhaps
he most significant risk factor in the development of
ervical carcinoma (reviewed in Garland et al., 1992).
The ability of E6 to interact with p53 is not, however,
he only explanation for its observed biological effects,
nd it has been reported that the HPV 16 E6 protein can
ffect several biological responses in a p53-independent
anner. For example, an early report demonstrated its
bility to affect both p53-dependent and p53-indepen-
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (404) 651-2509. E-mail: biopjd@panther.gsu.edu.
2 Current address: Centers for Disease Control and Prevention, Mail-
ttop C-02, Building 5-338, 1600 Clifton Road NE, Atlanta, GA 30333.
55ent apoptotic pathways (Pan and Griep, 1995). Other
53-independent effects of E6 include the in vivo re-
ponse to radiation-induced DNA damage (Song et al.,
998) and the growth regulation of cervical cancer cells
Fogel and Riou, 1998; Spitkovsky et al., 1996). In addi-
ion, while the ability of E6 to bind to p53 was required for
ts tumorigenicity and the decreased serum requirement
f expressing cells, p53 degradation was not (Inoue et
l., 1998). One important factor in the ability of E6 to
ransform cells may be its ability to activate telomerase;
his activation is also independent of its ability to cause
apid p53 degradation (Klingelhutz et al., 1996).
Mechanisms of E6 action likely involve interaction with
ellular proteins, and indeed, the HPV E6 protein has
ecently been reported to interact with a number of cel-
ular proteins in addition to p53 and E6-AP (reviewed in
ubbutat and Vousden, 1998). These include E6BP, a
alcium-binding protein (Chen et al., 1995); hDLG, a tu-
or suppressor, (Lee et al., 1997); IRF-3, an interferon
esponse factor (Ronco et al., 1998); paxillin, a focal
dhesion protein (Tong and Howley, 1997); and, at least
or the bovine papillomavirus E6 protein, the clathrin
daptor complex AP-1 (Tong et al., 1998). It is therefore
enable that the E6 protein has multiple functions.
We report here that expression of the E6 gene in LM
ells resulted in resistance of the transfectants to TNF-
riggered apoptosis. Because TNF treatment of LM cells
oes not lead to an increase in cellular p53 levels, and
ecause a mutant form of E6 that is unable to mediate
apid p53 degradation provides partial protection, this
rotection is most likely mediated through a mechanismhat does not require p53 degradation. Thus, HPV may
0042-6822/99 $30.00
Copyright © 1999 by Academic Press
All rights of reproduction in any form reserved.
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56 DUERKSEN-HUGHES, YANG, AND SCHWARTZave the capacity to block not only p53-mediated apop-
osis, but also apoptosis that is triggered by TNF.
RESULTS
ransfection of HPV 16 E6 provides protection
rom TNF
Although most cells are resistant to TNF in the ab-
ence of inhibitors of protein synthesis such as cyclo-
eximide, LM cells are spontaneously sensitive to the
ytokine (Gooding et al., 1990). This property made it
ossible to examine the effects of the HPV 16 E6 protein
n TNF sensitivity without the potential confounding ef-
ects of such inhibitors.
LM cells were cotransfected with pSV2neo, which
odes for resistance to G418, and either pSG16E6 or
1436. Both pSG16E6 and p1436 code for wild-type E6.
ollowing selection for neo-expressing cells by culture
ith G418, the pooled cells were treated with 100 u/ml
NF for 16 h. The results, shown in Fig. 1, indicate that
oth of the pooled populations transfected with HPV 16
6 are much less sensitive to TNF than are the parental
M cells.
ells stably expressing HPV 16 E6 display less
ensitivity to TNF
To further characterize this effect, stable cell lines
xpressing the HPV 16 E6 protein were created. LME6
FIG. 1. Response of E6-transfected, pooled populations to TNF. LM
ells were transfected with pSG516E6 or 1436 plus pSV2neo and
elected for expression of neo for two passages in selective medium.
he pooled populations, either untreated or treated with 100 units/ml
NF for 16 h, were harvested, lysed, and analyzed for evidence of cell
eath by the cell death ELISA. Each population was tested in triplicate,
nd the relative increase in cell death compared to that of the untreated
ells was calculated. The error bars represent the standard error of the
ean.nd JHE6 are stable cell lines formed following cotrans- bection of LM cells with pSV2neo and either pSG16E6 or
1436, respectively. These cells were treated with 100
/ml TNF for 16 h and analyzed for evidence of cell death.
s Fig. 2 shows, both lines showed significant protection
rom TNF-triggered apoptosis, as measured by the cell
eath ELISA. The level of protection differed quantita-
ively between the two lines and was greatest for the
ME6 cells; therefore, this line was chosen for further
nalysis.
ME6 expresses the E6 message and cannot
ccumulate p53
LME6 cells clearly express mRNA that encodes the
xpected E6 fragment (Fig. 3A, lane 2), while the un-
ransfected parental line, LM, and the negative control
ransfectant, LMN, do not (lanes 1 and 4, respectively).
vidence that the E6 protein is being produced and is
ctive in LME6 cells is presented in Fig. 3B. Both the
M and the LMN cells display measurable steady-
tate levels of p53 (approximately 2 to 3 ng p53/mg
rotein) and are capable of accumulating dramatically
ncreased amounts of p53 in response to treatment
ith a known genotoxin (mitomycin C). In the LME6
ells, however, there is no detectable baseline amount
f p53 and only a barely detectable level of p53 fol-
owing mitomycin C treatment. Because the HPV 16 E6
rotein is known to direct p53 degradation, this lack of
53 in the LME6 cells is consistent with the expected
ctivity of the gene product of the exogenously added
6 gene.
FIG. 2. Response of cloned cell lines stably transfected with E6 to
NF. LM, LME6, and JHE6 cells either untreated or treated with 100
nits/ml TNF for 16 h were harvested, lysed, and analyzed for evidence
f cell death by the cell death ELISA. Each sample was measured in
uplicate, and the absorbance of each sample was normalized to that
f the treated LM cells, where lysis was essentially complete. The error
ars represent the standard deviation.
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57HPV 16 E6 PROTECTS LM CELLS FROM TNFME6 cells are resistant to TNF-induced apoptosis
After treatment with 100 units/ml TNF for 24 h, the LM
nd the LMN cells were nearly completely lysed, while
he LME6 cells appeared relatively healthy (see Fig. 4).
o determine the dose range over which this difference
n cell viability was apparent, we treated the three cell
ines with several doses of TNF for 16 h, harvested the
ells, and quantitated the released, cytoplasmic nucleo-
omes by ELISA. The results are shown in Fig. 5A. As
een here, although both the LM and the LMN cells
nderwent significant death after incubation in TNF con-
entrations from 1 to 100 units/ml, the LME6 cells were
esistant at doses up to and including 100 u/ml. The
ncrease in apoptosis in treated LM and LMN cells be-
ame apparent at doses as low as 1 u/ml, and the effect
ncreased with increased dosage. The resistance to TNF
as also observed when LM and LME6 cells were
reated with 100 u/ml TNF and harvested at 4-h intervals
Fig. 5B). The LM cells demonstrated an increase in cell
FIG. 3. Characterization of transfected cell lines. (A) RNA from the
pecified cell lines was extracted and subjected to RT-PCR using
rimers R3 and L3, which correspond to the two ends of the E6 coding
equence. Lane 1, untransfected parental LM cells; lane 2, LME6 cells;
ane 3, LMD cells; lane 4, LMN cells; lane 5, JHE6 cells; lane 6, SiHa
ells. The arrow shows the expected migration position of the intact E6
NA. (B) LM, LMN, LMD, and LME6 cells were either untreated (solid
ars) or treated with 10 mg/ml mitomycin C (open bars) for 16 h and
arvested, and the lysates were subjected to ELISA analysis of their
53 levels. Each point was measured in triplicate and the error bars
epresent the standard error of the mean.eath as early as 8 h following treatment, with maximal tell death evident at 16 h posttreatment, while the level of
ell death in the LME6 cells was significantly lower.
The resistance of LME6 cells to TNF-triggered apopto-
is extends over 3 days (Fig. 5C). In this experiment, LM,
MN, and LME6 cells were treated with 100 u/ml TNF.
lates were harvested 1, 2, and 3 days posttreatment and
he percentage of viable cells was calculated following
rypan blue staining. Clearly, the percentage of viable
ME6 cells was significantly greater than that seen with
he LM and LMN cells following TNF treatment.
Not only do the LME6 cells remain alive in the pres-
nce of TNF, but they retain their ability to proliferate.
igure 6 shows the total number of LM, LMN, and LME6
ells following treatment with 100 u/TNF for 1, 2, and 3
ays. While there is no increase in the number of treated
M or LMN cells with time, the proliferation of treated
ME6 cells is roughly equivalent to that of the untreated
ontrols; the numbers of both the treated and the un-
reated LME6 cells increase by approximately 13-fold
ithin 3 days. Therefore, in contrast to the parental LM
ell line, neither the viability nor the ability of LME6 cells
o proliferate is significantly compromised by the pres-
nce of 100 u/ml TNF.
NF-induced apoptosis does not correlate with
ncreased levels of cellular p53
The best-characterized function of the HPV E6 protein
s the mediation of p53 degradation. We, therefore, next
etermined whether the TNF-protective function of E6 on
M cells could be accounted for by the effect of E6 on
53 degradation. Following DNA damage, p53 levels first
ise, and then the cells undergo growth arrest and/or
poptosis (Fritsche et al., 1993) (also see Fig. 3B). If
NF-triggered apoptosis also requires p53, TNF treat-
ent would be expected to increase cellular p53 levels,
hich would in turn mediate apoptosis.
LM cells treated with several doses of TNF were
nalyzed for their levels of p53 16 h following treatment
Fig. 7A). Cellular p53 levels in these cells did not in-
rease following TNF treatment, but remained relatively
table in cells treated with the low doses and fell in the
ells treated with the highest doses of TNF (10 and 100
/ml), in which apoptosis was actually occurring. When
ells were treated with 100 u/ml TNF and harvested at
-h intervals, we found that the level of p53 did not rise
ignificantly at times prior to the visible development of
poptosis (12 h), at which point the level of p53 fell (Fig.
B). These data suggest that TNF is causing apoptosis of
M cells through a pathway that does not initially involve
53, suggesting that E6 is most likely protecting LM cells
rom TNF-induced apoptosis by an alternative mecha-
ism. As expected, the LME6 cells did not contain de-
ectable amounts of cellular p53 either before or after
reatment with TNF (data not shown).
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58 DUERKSEN-HUGHES, YANG, AND SCHWARTZells expressing an E6 mutant can accumulate p53,
et are protected from TNF-mediated apoptosis
To further examine the mechanism of protection from
NF-induced apoptosis by E6, we utilized a mutant form
f E6 that was previously reported to be unable to bind
nd degrade p53 (Crook et al., 1991; Lechner et al., 1992).
plasmid encoding this mutant E6 gene, pSG16E6D106-
10, was cotransfected with pSV2neo into LM cells. Fol-
owing cell selection and cloning, RT-PCR screening was
sed to identify two cell lines that expressed the trans-
ected gene. One of these cell lines, LMD, was chosen
or a more detailed analysis. Figure 3A, lane 3 demon-
trates expression of the mutant E6 mRNA in these cells.
MD cells also demonstrate no decrease in their base-
ine levels of p53 protein nor in their ability to accumulate
FIG. 4. Effect of TNF on cell morphology. LM, LMN, and LME6 cells
ells were photographed using a Sedival aus Jena inverted microscopigh levels of the protein following treatment with mito- Tycin C for 16 h (Fig. 3B), indicating that this mutant form
f E6 is indeed unable to direct significant degradation of
53 in LM cells.
Despite the inability of this mutant E6 to mediate the
apid degradation of p53, we found that LMD cells that
ere treated with TNF were significantly, though not
ompletely, protected from TNF-induced apoptosis. The
elative protection from apoptosis was observed micro-
copically following treatment with 100 units/ml TNF for
4 h (compare Fig. 8A with Fig. 4) and detected by ELISA
t 4-h intervals following treatment with 50 u/ml TNF (Fig.
B). This partial protection could also be measured by
rypan blue exclusion of treated and untreated cells over
period of 3 days (Fig. 8C).
Not only were the LMD cells partially protected from
ntreated (0 h) or treated with 100 units/ml TNF for 24 h as indicated.
03 magnification.were uNF-triggered apoptosis, they were able to proliferate in
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59HPV 16 E6 PROTECTS LM CELLS FROM TNFhe presence of the cytokine (Fig. 9), although the prolif-
ration was not as vigorous as seen in the TNF-treated
ME6 cells (Fig. 6). Together, these data indicate that
ells stably transfected with a mutant E6, which is unable
o mediate rapid p53 degradation, are partially protected
rom TNF-triggered apoptosis.
DISCUSSION
We found that LM cells, which are normally suscepti-
le to TNF-mediated apoptosis, become resistant to the
ytolytic effects of this cytokine when stably transfected
ith the gene coding for wild-type HPV 16 E6. This
FIG. 6. Effect of TNF on cellular proliferation. LM (A), LMN (B), and
ME6 (C) cells were plated into separate wells of 12-well plates (1 3
05 cells per well). Cells were then treated with 100 units/ml TNF. At
he end of 1, 2, and 3 days, wells (three per time point) were
arvested and treated with trypan blue, and the number of viable
ells was counted twice for each well. Error bars represent theFIG. 5. Effect of TNF on cell death and viability. (A) LM (}), LMN (),
nd LME6 (n) cells were treated with the specified doses of TNF for
6 h, harvested, and analyzed for evidence of cell death by a cell death
LISA that quantitates the amount of cytoplasmic nucleosomes. Re-
ults are reported as the percentage of the absorbance value obtained
rom LM cells treated with TNF for 16 h, where lysis is essentially
omplete. Each lysate was analyzed for cell death in duplicate and the
rror bars represent the standard deviation. (B) LM (}) and LME6 (n)
ells were treated with 100 units/ml TNF for the specified times,
arvested, and analyzed for evidence of cell death by the cell death
LISA. Results are reported as the percentage of the absorbance value
btained from LM cells treated with TNF for 16 h, where lysis is
ssentially complete. The error bars represent the standard error as
alculated from two independent experiments. (C) LM (}), LMN (),
nd LME6 (n) cells were treated with 100 units/ml TNF. At the end of 1,
, and 3 days, plates (three per time point) were harvested, and the
ells were stained with trypan blue (0.4%) and counted. The number of
ive cells is reported as a percentage of the total cell number, and error
tandard deviation.
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60 DUERKSEN-HUGHES, YANG, AND SCHWARTZesistance was detected by several methods, including
he morphology of treated and untreated cells, the time-
nd dose-dependence of cell death as measured by a
uantitative cell death ELISA, cell survival over 3 days,
nd cell proliferation over 3 days.
The best-characterized function of the HPV E6 gene is
ediation of the degradation of p53 (Scheffner et al.,
990, 1993). Because TNF can initiate apoptosis and p53
an mediate it, it was possible that TNF could be medi-
ting apoptosis in LM cells via a p53-dependent mech-
nism and that the expression of the E6 gene protected
he LM cells by eliminating p53. However, TNF treatment
f the parental LM cells did not result in an increase in
53. This suggested that TNF-mediated apoptosis of
hese cells could occur by a p53-independent pathway
nd that the protective effect of the HPV 16 E6 gene
ccurred by a mechanism other than p53 degradation. In
upport of this model, we observed that cells expressing
mutant E6 gene, whose gene product was unable to
liminate p53, were partially protected from TNF-trig-
ered apoptosis, as indicated by morphological analysis,
ell death ELISA, and measurements of cell survival and
ell proliferation over 3 days.
FIG. 7. Response of cellular p53 to TNF exposure. (A) LM cells were
reated with the specified doses of TNF for 16 h, harvested, and
nalyzed for their p53 levels by ELISA. (B) LM cells were treated with
00 units/ml TNF for the specified times, harvested, and analyzed for
heir p53 levels by ELISA. Each point was measured in triplicate and
he error bars represent the standard deviation.The accumulating evidence indicates that while TNF and n53 both function in pathways leading to apoptosis, at least
he initial steps of the two pathways are distinct. Apoptosis
riggered by TNF is thought to result from a sequence of
FIG. 8. Partial resistance of LMD cells to TNF. (A) LMD cells were
ntreated (0 h) or treated with 100 units/ml TNF for 24 h as indicated.
ells were photographed using a Sedival aus Jena inverted micro-
cope at 2003 magnification. (B) LM (}), LMD (n), and LME6 () cells
ere treated with 50 units/ml TNF for the indicated times, harvested,
nd analyzed for evidence of cell death by the cell death ELISA. Each
oint was measured in duplicate and the error bars represent the
tandard deviation. (C) LM and LMD cells were treated with 50 units/ml
f TNF. At the end of 1, 2, and 3 days, plates (three per time point) were
arvested, and the cells were stained with trypan blue and counted.
he number of live cells is reported as a percentage of the total cell
umber, and error bars represent the standard deviation.
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61HPV 16 E6 PROTECTS LM CELLS FROM TNFignals that begins when trimeric TNF binds to and cross-
inks its receptor (TNFR1). The cross-linked receptors then
nitiate a chain of activation events, proceeding sequentially
hrough proteins called TRADD and FADD to caspase 8,
hich leads into the central cell death pathway and the final
vents of apoptosis (reviewed in Ashkenazi and Dixit
1998)). p53-mediated apoptosis, on the other hand, is ini-
iated by cellular stressors such as DNA damage, which
ause an increase in the level of activated cellular p53. p53
s a transcriptional activator and exerts its effects such as
rowth arrest and apoptosis through turning on a variety of
enes including p21/waf1/cip1 and bax (reviewed in Hall et
l. (1996)). Consistent with the proposed separation of the
nitial steps, BT-20 cells, which possess mutant p53, and
L-60 cells, which lack p53, are TNF sensitive (see Bartek
t al. (1990); Bellomo et al. (1992); Kang et al. (1998); Shio-
ara et al. (1996) and references therein). It is likely that the
ater steps of both of these apoptosis pathways, such as
he activation of the caspase cascade, endonuclease acti-
ation, and the clipping of the DNA into nucleosomal frag-
ents, are common to both pathways.
FIG. 9. Effect of TNF on proliferation of LMD cells. LM and LMD cells
ere plated into separate wells of 12-well plates (1 3 105 cells per
ell). Cells were then treated with 50 units/ml TNF. At the end of 1, 2,
nd 3 days, wells (three per time point) were harvested and treated
ith trypan blue, and the number of viable cells was counted twice for
ach well. Error bars represent the standard deviation.However, the suggestion has been made that p53 Eould be important in TNF-mediated apoptosis in some
ells. Treatment of some cells, including rat glioma cells
Yin et al., 1995), ME-180 (Donato and Perez, 1998), RAT1-
yc ER (Klefstrom et al., 1997), and SNU-16 (Park et al.,
998) with TNF leads to increases in p53 and the induc-
ion of cell death. However, it has not yet been proven
hat these p53 increases are directly responsible or nec-
ssary for TNF-mediated apoptosis. It should be noted
hat the effects of TNF can vary greatly in different cell
ypes; it is possible that TNF mediates cytolysis by dif-
erent pathways in different cells.
Our results indicate that the HPV 16 E6 gene can
unction to block TNF-triggered apoptosis in LM cells
nd provide evidence that p53 induction is not required
or this apoptosis. These findings are not consistent with
mechanism in which binding of TNF to its receptor
ctivates various cellular messengers, resulting in acti-
ation and stabilization of p53 followed by apoptosis.
revious work with inducers of p53-mediated apoptosis
as shown that while p53 stabilization and activation are
istinct functions that likely involve differential phosphor-
lation and dephosphorylation of specific residues
Chernov et al., 1998; Meek et al., 1997; Shieh et al.,
997), both occur following DNA damage. Our results do
ot rule out the possibility that although TNF does not
nitially increase p53 levels, it could be activating avail-
ble p53 for apoptosis induction.
The ability of the mutant E6 gene to confer significant,
hough not complete, protection when expressed in LM
ells, even though it did not decrease p53 levels, also
rgues that E6 is acting, at least in part, by a mechanism
hat does not require p53 degradation to protect cells
rom TNF. We cannot completely rule out the possibility
hat E6 could inhibit, in whole or in part, p53 function in
MD cells without causing its degradation. It has been
eported, for example, that the ability of HPV 18 E6 to
nhibit the ability of p53 to bind to DNA is independent of
ts ability to induce its degradation (Thomas et al., 1995).
In addition to the possibility, mentioned above, that the
utant E6 has the potential to partially inactivate p53,
here are other possible explanations for our observation
hat the LMD cells are only partially protected from TNF.
ne is that the mutant protein is partially defective for its
53-independent activities due to the deletion. Another is
hat the mutant protein is simply less abundant in these
ells than is the E6 protein in the LME6 cells. In this
egard, we note that the JHE6 cells, which were also
ransfected with the wild-type E6 protein, exhibit only
artial protection from TNF (Fig. 2).
Thus far, the HPV E6 protein has been shown to
nteract with several cellular proteins. Two of these, the
53 and E6AP proteins, are involved in the p53-mediated
egradation pathway. Although our results suggest that
53 degradation is not necessary for protection from
NF, it may be that the binding of E6 to E6AP could make
6AP less available to interact with its normal substrate
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62 DUERKSEN-HUGHES, YANG, AND SCHWARTZr substrates. This alteration could be responsible for the
bserved protection from TNF. Other E6-binding proteins
ave also been identified. The E6BP protein may be
nvolved in cell differentiation, IRF-3 is an important reg-
lator of interferon gene activity, and paxillin and hDLG
re important in cell–cell contact and signaling (see
ubbutat and Vousden (1998) and references therein);
hese functions could very well be important in transduc-
ng and executing apoptotic and other signals that are
ctivated by TNF binding. Also, E6 may interact with
dditional, as-yet-unidentified cellular proteins.
Recently, Elston et al. (1998) used a 16-mer peptide
ibrary to identify peptides that interacted specifically
ith HPV 16 E6. From this work, a E-L-L/V-G motif was
dentified. On analyzing the published sequence of
RADD (Hsu et al., 1995), which plays a major role in
NF-triggered apoptosis, this group recently identified an
LLG motif at the C-terminus of TRADD, as well as a
axillin-like motif in the same molecule (Elston, personal
ommunication). If HPV 16 E6 does indeed bind to and
equester and/or inactivate TRADD, this could explain its
ffect on the TNF sensitivity of LM cells.
The ability of HPV 16 E6 to inhibit TNF-mediated apop-
osis may be somewhat strain and/or cell type specific.
eLa cells, for example, have HPV 18 sequences incor-
orated into their genome. However, when infected by
denovirus mutants lacking the TNF protective functions,
hey are lysed by TNF (Gooding et al., 1991), indicating
hat the HPV 18 E6 gene does not protect them from the
ytokine in these circumstances. Thus, the HPV 16 E6
ay differ from HPV 18 E6 in its ability to protect express-
ng cells from TNF-mediated apoptosis. Alternatively, the
ifference in cell types (mouse fibroblast LM cells versus
uman cervical carcinoma HeLa cells) may account for
he different results. There may also be differences in the
mount of E6 expressed in the two cell types, and it
hould also be noted that additional virus proteins ex-
ressed by the infected HeLa cells (for example, E7)
ould modulate the final phenotype.
Adenovirus and HPV 16 have previously been shown
o possess two common strategies for evading host
efenses: the abrogation of p53 function (carried out by
he adenovirus 55-kDa protein and the HPV 16 E6 pro-
ein) (Braithwaite et al., 1991; Huibregtse et al., 1991;
cheffner et al., 1990, 1993; Yew et al., 1994) and the
inding to and inhibition of the retinoblastoma protein
observed with the adenovirus through its E1A protein
nd the papillomavirus through its E7 protein) (Dyson et
l., 1989; Whyte et al., 1988). We report here that HPV 16
ossesses a third immune evasion strategy in common
ith adenovirus, namely, the ability to interfere with TNF-
ediated apoptosis. In the case of the adenoviruses, this
unction is carried out by three E3-encoded proteins and
ne E1B-encoded protein (reviewed in Gooding (1994)).
n the case of the HPV 16, the ability to interfere with
NF-mediated apoptosis is carried out by the same pro- pein that interferes with p53-mediated apoptosis, the E6
rotein. The adenovirus and papillomaviruses, therefore,
ave both acquired several similar strategies to maintain
nfections in cells, but the apportioning of these functions
o the various viral proteins differs between these virus
roups.
MATERIALS AND METHODS
ell culture
LM cells are mouse fibroblasts obtained from the
TCC and are sensitive to TNF (Gooding et al., 1990).
ntibodies specific for wild-type p53 (Ab-1) (CalBiochem,
ambridge, MA) were capable of immunoprecipitating
53 from these cells, suggesting the presence of the
ild-type allele (data not shown). LM cells were propa-
ated in minimal essential medium supplemented with
0% fetal bovine serum (MEM 10) (Gibco/Life Sciences,
aithersburg, MD). CaSki cells were derived from a hu-
an carcinoma and were obtained from the ATCC. They
re known to carry the HPV16 E6 gene (Smotkin and
ettstein, 1986) and were cultivated in RPMI medium
upplemented with 10% fetal bovine serum.
lasmids
pSVneo carries a gene for G418 resistance (Southern
nd Berg, 1982). pSG16E6 and p1436 both incorporate
he wild-type sequence from HPV type 16, while
SG16E6D106-110 encodes a mutant form of the E6 pro-
ein that is defective in the ability to bind and degrade
53 (Crook et al., 1991; Lechner et al., 1992). pSG16E6
nd pSG16E6D106-110 were generously provided by La-
onis A. Laimins and were derived from the constitutive
SG5 eukaryotic expression vector (Stratagene, La Jolla,
A), which includes the early SV40 promoter for in vivo
xpression and the T7 promoter for in vitro transcription.
1436 (Munger et al., 1989) was provided by Jon
uibregtse and contains the E6 ORF followed by a dis-
upted E7 ORF in p1318, a b-actin expression vector.
ransfection and testing of pooled cell populations
LM cells were plated at a concentration of 1 3 106
ells per plate 24 h prior to transfection. Transfections
ere carried out using LipofectAmine as directed by the
anufacturer (Gibco BRL, Gaithersburg, MD); the trans-
ection mixtures contained 4 mg pSG16E6 or p1436 DNA
lus 0.4 mg pSV2neo DNA. Cells were transferred to
elective medium (MEM 10 supplemented with 400
g/ml G418 (Gibco BRL)) and used within two passages.
To determine the sensitivity of these pooled popula-
ions to TNF, the wells of a 96-well plate were seeded
ith cells (3 3 103 cells per plate). Six h later, the
ndicated concentrations of TNF (Genzyme, Cambridge,
A) were added and the incubation was allowed toroceed for the specified times, after which lysates were
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63HPV 16 E6 PROTECTS LM CELLS FROM TNFrepared and analyzed for evidence of cell death using
he cell death ELISA (Boehringer Mannheim, Indianapo-
is, IN). The results were analyzed using the following
ormula:
@Absorbance at 405 nm (treated cells)
2 Absorbance at 405 nm (untreated cells)#
Absorbance at 405 nm (untreated cells)
3 100.
ransfection and preparation of stable cell lines
LM cells were plated at a concentration of 2 3 106
ells per plate 24 h prior to transfection. Transfections
ere carried out using LipofectAmine as directed by the
anufacturer (Gibco BRL); the transfection mixtures con-
ained 18 mg pSG16E6, p1436, or pSG16E6D106-110 DNA
lus 2 mg pSV2neo DNA, or 2 mg pSV2neo DNA alone. At
2 h posttransfection, the cells were passaged at a split
atio of 1:4 in selective medium. Distinguishable colonies
ppeared within 10–14 days posttransfection. Colonies
ere isolated using cloning rings, transferred into indi-
idual wells, and expanded into individual clones, which
ere subsequently grown in selective medium. Three
table cell lines were obtained and screened by RT-PCR
ollowing cotransfection of p1436 and pSV2 neo. Of
hese, two lines expressed the E6 mRNA. One cell line,
HE6, was selected for further analysis. Eight stable cell
ines were obtained and screened by RT-PCR following
otransfection of pSG16E6 and pSV2neo. Of these, one
ell line, LME6, expressed the E6 mRNA. Five stable cell
ines were obtained and screened by RT-PCR following
otransfection with pSG16E6D106-110 and pSV2neo. Of
hese, two lines expressed the E6 mRNA. One of these
lones, LMD, was selected for further analysis. LMN is a
esult of transfection with pSV2neo alone.
T-PCR
Transfected cells were screened for expression of E6
y RT-PCR. RNA from LM, LMN, LMD, LME6, and JHE6
ells was harvested using Tri Reagent (Molecular Re-
earch Center, Inc., Cincinnati, OH) according to the
anufacturer’s protocol. RNA samples from SiHa and
aSki cells were used as positive controls, and RNA
rom LMN cells provided a negative control. One micro-
ram of RNA from a transfected clone was added as a
emplate, and oligonucleotide R (GCATAAATCCCGAAA-
GCAA), corresponding to nucleotides 172–191 of the E6
ene, was used as the primer. Reverse transcription by
he enzyme from avian myeloblastosis virus was carried
ut as described by the manufacturer (Gibco BRL). The
DNA was precipitated with ethanol and stored at
20°C overnight. Samples were centrifuged for 45 min
t 14,000 rpm. The cDNA pellet was washed with 70%
thanol and air-dried.
Oligonucleotide R (see above) and either oligonucle-
tide L1 (ACTGCAATGTTTCAGGACCC), which corre- pponds to nucleotides 33–53 of the E6 gene, or L2 (AGC-
ACCCAGAAAGTTACCA), which corresponds to nucle-
tides 58–77 of the E6 gene, were used as primers for
he PCR. L1 was used as the primer while screening for
xpression of the wild-type E6 gene and L2 as the primer
hen screening for expression of the mutant E6 gene.
riefly, 1 ml of each primer at a concentration of 100
mol/ml was added to the cDNA pellets, after which 100
l of the PCR mixture (70 ml 103 buffer, 5.6 ml dNTPs, 3.5
l Taq polymerase, 614 ml deionized water) was added.
CR was performed using the GeneAmp PCR Reagent
it with native Taq polymerase (Perkin–Elmer, Norwalk,
T) under conditions recommended by the manufacturer.
he amplification protocol consisted of 40 cycles of 1
in at 50°C, 2 min at 72°C, and 1 min at 94°C.
Results obtained using these methods were confirmed
y pairing primer L3, which corresponds to the N-termi-
al end of E6 (ATGTTTCAGGACCCACAGG), with either
3, which corresponds to the C-terminal end of E6 (TTA-
AGCTGGGTTTCTCTACG), or with poly(T), in incuba-
ions with RT-PCR beads (Pharmacia, Piscataway, NJ)
ccording to the manufacturer’s instructions. In separate
xperiments (not shown), amplifications following pre-
reatment of the RNA with DNase yielded a similar pat-
ern of products that were present in amplifications done
ith RT-PCR beads, but absent in amplifications done
ith PCR beads (lacking the RT enzyme).
reatment of cells with mitomycin C
To determine the ability of the transfected cell lines
o accumulate increased levels of p53 following DNA
amage, cells were treated with mitomycin C and
ssayed for the resulting p53 levels. Here, 100-mm
lates were seeded with 1 3 106 cells per plate and
llowed to incubate overnight. Approximately 24 h
ater, mitomycin C was added to a final concentration
f 10 mg/ml medium. Sixteen hours later, cells were
arvested and the lysates analyzed for p53 by ELISA
s described below.
reatment of cells with TNF
Twenty-five- (12 wells/plate) or 100-mm plates were
eeded with cells (5 3 104 or 1 3 106 cells per plate,
espectively) and incubated overnight at 37°C in a 5%
O2 incubator. Approximately 24 h later, the indicated
oncentrations of TNF (Genzyme) were added and the
ncubation was allowed to proceed for the specified
imes, after which lysates were prepared and analyzed
or evidence of cell death or the concentration of p53.
53 ELISA
Cells were removed from the 100-mm plates by trypsin
reatment (0.25 mg/ml, Worthington, Freehold, NJ) and
elleted by centrifugation at 1000 rpm for 10 min. The cell
ellet was then treated with lysis buffer (20 mM Tris, 150
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64 DUERKSEN-HUGHES, YANG, AND SCHWARTZM NaCl, 1% NP-40, pH 8.0, 1% aproteinin) for 20 min on
ce, and membrane fragments were removed by centrif-
gation at 14,000 rpm for 15 min. The protein concentra-
ion of the cleared lysate was determined by the bicin-
honinic acid assay (Pierce, Rockford, IL).
Cell lysates were diluted 1:10 in PBS containing 10%
etal calf serum (PBS 10) and subjected to ELISA analysis
s described previously (Yang and Duerksen-Hughes,
998). pAb122 was used as the capture antibody, and
iotinylated, polyclonal anti-p53 (Boehringer Mannheim)
as the secondary antibody. GST-p53 (Santa Cruz Bio-
echnology, Inc., Santa Cruz, CA) was used as a stan-
ard. The p53 concentration of each sample was mea-
ured in triplicate.
ell death ELISA
This assay was performed using a commercially avail-
ble kit (cell death ELISA) (Boehringer Mannheim), which
easures the presence of cytoplasmic nucleosomes.
lates containing the treated cells were centrifuged
1500 rpm for 10 min) and the medium was removed by
spiration. Lysates were then prepared as directed by
he manufacturer. Equal cell equivalents were added to
ells to which the anti-histone antibody was fixed ab-
orptively and the ELISA was carried out according to
he manufacturer’s instructions. The concentration of cy-
oplasmic nucleosomes in each sample was measured
n duplicate.
ell proliferation and viability assays
Cells were seeded at approximately 1 3 105 cells/well
n flat-bottomed 12-well dishes (Corning) and grown in 3
l of medium. After treatment, cells were harvested with
.25% trypsin and cell number was determined by trypan
lue exclusion (0.4%).
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